[Skip to Content]
[Skip to Content Landing]
Editorial
January 9, 2018

Lack of Benefit With Idalopirdine for Alzheimer DiseaseAnother Therapeutic Failure in a Complex Disease Process

Author Affiliations
  • 1Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, Ilinois
JAMA. 2018;319(2):123-125. doi:10.1001/jama.2017.19700

Alzheimer disease is a large and growing public health problem that has prompted governments around the world, including in the United States, to develop national plans to address the disease.1 However, medications approved for the treatment of Alzheimer disease provide little symptomatic benefit, and the most recent approval by the US Food and Drug Administration occurred in 2003 (not including reformulations).

First Page Preview View Large
First page PDF preview
First page PDF preview
×